Beovu Injection, Solution
Product Images NDC 0078-0827

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Beovu (NDC 0078-0827). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Preparation For Administration (Store BEOVU in the refrigerator between 2 to 8°C (36 to 46°F); do not freeze. Keep the vial in the outer carton to protect from light.)

Preparation For Administration (Store BEOVU in the refrigerator between 2 to 8°C (36 to 46°F); do not freeze. Keep the vial in the outer carton to protect from light.)
FDA Label Image

Preparation For Administration (Prior to use, the unopened glass vial of BEOVU may be kept at room temperature, 20 to 25°C (68 to 77°F) for up to 24 hours. After opening the glass vial, proceed under aseptic conditions.)

Preparation For Administration (Prior to use, the unopened glass vial of BEOVU may be kept at room temperature, 20 to 25°C (68 to 77°F) for up to 24 hours. After opening the glass vial, proceed under aseptic conditions.)
FDA Label Image

Preparation For Administration (BEOVU is a clear to slightly opalescent and colorless to slightly brownish-yellow solution.)

Preparation For Administration (BEOVU is a clear to slightly opalescent and colorless to slightly brownish-yellow solution.)
FDA Label Image

Preparation For Administration (BEOVU should be inspected visually upon removal from the refrigerator and prior to administration. If particulates, cloudiness, or discoloration are visible, the glass vial must not be used. The BEOVU kit includes the sterile glass vial and filter needle which are for single use only. Do not use if the packaging, vial and/or filter needle are damaged or expired [see How Supplied/Storage and Handling (16)].)

Preparation For Administration (BEOVU should be inspected visually upon removal from the refrigerator and prior to administration. If particulates, cloudiness, or discoloration are visible, the glass vial must not be used. The BEOVU kit includes the sterile glass vial and filter needle which are for single use only. Do not use if the packaging, vial and/or filter needle are damaged or expired [see How Supplied/Storage and Handling (16)].)
FDA Label Image

Figure 1: (Rth258 05)

Figure 1: (Rth258 05)
FDA Label Image

Figure 2: (Rth258 06)

Figure 2: (Rth258 06)
FDA Label Image

Figure 3: (Rth258 07)

Figure 3: (Rth258 07)
FDA Label Image

Figure 4: (Rth258 08)

Figure 4: (Rth258 08)
FDA Label Image

Figure 5: Mean Change In Visual Acuity From Baseline To Week 96 In Hawk (Rth258 09)

Figure 5: Mean Change In Visual Acuity From Baseline To Week 96 In Hawk (Rth258 09)
This is a chart that displays BCVA (best corrected visual acuity) changes from baseline in letters over a span of 96 weeks for two drugs - BEOVU and Aflibercept 2mg. The study was called HAWK and involved 360 participants for each drug. The horizontal axis represents time in weeks while the vertical axis depicts the change in BCVA in letters.*
FDA Label Image

Figure 6: Mean Change In Visual Acuity From Baseline To Week 96 In Harrier (Rth258 10)

Figure 6: Mean Change In Visual Acuity From Baseline To Week 96 In Harrier (Rth258 10)
FDA Label Image

Principal Display Panel Ndc 0078 0827 61 Beovu (brolucizumab-dbll) Injection 6 mg/0.05 mL Single-dose Vial; Discard Unused Portion. For Intravitreal Use Carton Contains: 1 X 2 mL Vial, 1 X Filter Needle Novartis (Rth258 11)

Principal Display Panel Ndc 0078 0827 61 Beovu (brolucizumab-dbll) Injection 6 mg/0.05 mL Single-dose Vial; Discard Unused Portion. For Intravitreal Use Carton Contains: 1 X 2 mL Vial, 1 X Filter Needle Novartis (Rth258 11)
Beovu is a medication used for injection in treating certain eye conditions. It is designed to be stored in an unopened, refrigerated vial and discarded if unused. Each vial contains 0.05 mL of a solution containing 6mg/0.05mL of brolucizumab-dbll. Once opened, the un-used glass vial of Beovu can be kept at room temperature for 24 hours. Additional dosage and prescribing information are available on the manufacturer's website or by calling the company directly. The medication is manufactured by Novartis Pharmaceuticals Corporation.*
FDA Label Image

Rth258 12

Rth258 12
This looks like a description of a syringe. It has a cap and finger grip for easy handling, and a rubber stopper to prevent leakage. It appears to be calibrated in 0.05mL increments and has a Luer Lock mechanism to securely attach a needle. The plunger rod is also mentioned, likely used to control the amount of fluid drawn or dispensed.*
FDA Label Image

Rth258 13

Rth258 13
FDA Label Image

Rth258 14

Rth258 14
FDA Label Image

Rth258 15

Rth258 15
FDA Label Image

Rth258 16

Rth258 16
The text appears to be a chart depicting the change in visual acuity (VA) from baseline in letters, for two different treatments (Beovu and Aflibercept) over a period of 52 weeks. The first column represents the week number, and the subsequent columns represent the VA change in letters at corresponding weeks. There are some missing values denoted by dashes. The sample size (N) for both treatments is also provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.